S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:RCM

R1 RCM Stock Forecast, Price & News

$21.18
+0.05 (+0.24 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$20.85
Now: $21.18
$21.53
50-Day Range
$16.96
MA: $18.95
$20.88
52-Week Range
$7.12
Now: $21.18
$21.53
Volume945,153 shs
Average Volume1.18 million shs
Market Capitalization$2.47 billion
P/E Ratio211.82
Dividend YieldN/A
Beta0.57
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.
R1 RCM logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
Current SymbolNASDAQ:RCM
CUSIP00438V10
Phone(312) 324-7820
Employees22,500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$0.77 per share
Book Value$0.16 per share

Profitability

Net Income$12 million

Miscellaneous

Market Cap$2.47 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableNot Optionable
$21.18
+0.05 (+0.24 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











R1 RCM (NASDAQ:RCM) Frequently Asked Questions

How has R1 RCM's stock price been impacted by COVID-19 (Coronavirus)?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCM shares have increased by 108.5% and is now trading at $21.18.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of R1 RCM?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for R1 RCM
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than R1 RCM?

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for R1 RCM
.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) announced its earnings results on Tuesday, November, 3rd. The healthcare provider reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.11. The healthcare provider had revenue of $307.20 million for the quarter, compared to analysts' expectations of $295.38 million. R1 RCM had a net margin of 4.02% and a return on equity of 182.08%. R1 RCM's revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.01 earnings per share.
View R1 RCM's earnings history
.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2020 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.25-1.26 billion, compared to the consensus revenue estimate of $1.24 billion.

What price target have analysts set for RCM?

5 brokerages have issued 1-year price objectives for R1 RCM's stock. Their forecasts range from $12.00 to $26.00. On average, they anticipate R1 RCM's share price to reach $19.80 in the next twelve months. This suggests that the stock has a possible downside of 6.5%.
View analysts' price targets for R1 RCM
.

Are investors shorting R1 RCM?

R1 RCM saw a decrease in short interest in November. As of November 15th, there was short interest totaling 3,790,000 shares, a decrease of 23.9% from the October 31st total of 4,980,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 2.5 days.
View R1 RCM's Short Interest
.

Who are some of R1 RCM's key competitors?

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology Group (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Joseph Gerard Flanagan, President, Chief Executive Officer & Director
  • Rachel Wilson, Chief Financial Officer, Treasurer & Executive VP
  • Julia Davis, Chief Information Officer & Executive VP
  • Corey Perman, Executive Vice President-Compliance & Risk
  • M. Sean Radcliffe, Executive Vice President & General Counsel

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.46%), Paradigm Capital Management Inc. NY (3.56%), State Street Corp (2.86%), SCW Capital Management LP (2.05%), Snyder Capital Management L P (1.28%) and Boston Partners (1.21%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff, Joseph Gerard Flanagan and Michael C Feiner.
View institutional ownership trends for R1 RCM
.

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including SCW Capital Management LP, Penn Capital Management Co. Inc., Paradigm Capital Management Inc. NY, Point72 Asset Management L.P., Copper Rock Capital Partners LLC, New York State Common Retirement Fund, Royce & Associates LP, and Federated Hermes Inc..
View insider buying and selling activity for R1 RCM
.

Which institutional investors are buying R1 RCM stock?

RCM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Snyder Capital Management L P, State Street Corp, Principal Financial Group Inc., Anqa Management LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Public Sector Pension Investment Board, and Morgan Stanley. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM
.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $21.18.

How big of a company is R1 RCM?

R1 RCM has a market capitalization of $2.47 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

What is R1 RCM's official website?

The official website for R1 RCM is www.r1rcm.com.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.